Fresenius Medical Care Showcases Global Research Leadership at World’s Largest Gathering of Kidney Professionals
November 02 2017 - 2:21PM
Business Wire
Fresenius Researchers and Clinical Experts
from across the Globe Present More Than 75 Abstracts at the
American Society of Nephrology’s 2017 Kidney Week Symposium,
Demonstrating Commitment to Innovating Healthcare through
Science
Fresenius Medical Care North America (FMCNA), the premier health
care company focused on providing the highest quality care to
people with renal and other chronic conditions, today announced
that company researchers and clinical experts from across the globe
will present 77 research abstracts at the 2017 American Society of
Nephrology’s (ASN) Kidney Week Symposium, the largest and most
influential gathering of kidney professionals in the world.
Scheduled from Oct. 31 – Nov. 5, 2017, at the Ernest N. Morial
Convention Center in New Orleans, the annual symposium draws more
than 13,000 physicians, scientists and healthcare professionals
from over 100 countries, this year accepting a total of 92
abstracts of research work conducted or sponsored by Fresenius
Medical Care.
“The scope of our research and quality improvement builds on our
strength as the world’s largest, vertically integrated health care
company,” said Bill Valle, chief executive officer of Fresenius
Medical Care North America. “The data we collect allows us to use
sophisticated predictive analytics to further enhance patient care
at a personalized level and improve outcomes for our patients.”
With a focus on chronic kidney disease (CKD), end-stage renal
disease (ESRD) and adjacent medical conditions, the company’s
research crosses seven diverse categories:
- Using science and technology to
characterize and improve patient outcomes
- Driving advancements in management
paradigms through value based care models
- Using predictive modeling for clinical
decision support and better outcomes
- Characterizing the impacts of CKD
options education on outcomes and modality selection
- Leveraging coordinated care initiatives
to improve patient outcomes
- Defining outcomes related to the
management of bone mineral metabolism in renal disease
- Identifying the influences of social
determinants of health on clinical measures
“The breadth and depth of our leadership in advancing science
into clinical practice underscores our mission to improve the lives
of people with kidney and chronic diseases,” says Franklin W.
Maddux, MD, chief medical officer and executive vice president of
clinical and scientific affairs for Fresenius Medical Care North
America. “In blending patient perspectives with real world evidence
and traditional research, we are able to translate science into
clinical practice that ultimately improves the lives of the
patients who entrust us with their care.”
Highlights of key Fresenius Medical Care presentations at the
2017 ASN Kidney Week include:
- Association of Peridialytic Systolic
Blood Pressure Change and Pre-dialysis Systolic Blood Pressures on
Mortality among Hemodialysis Patients. This research
investigated if blood pressure patterns before and changes during
hemodialysis alter mortality rates. This oral presentation will be
given by Hanjie Zhang, MS on Thursday, Nov. 2 at 5:42 p.m. in room
277 (TH-OR007).
- Quasi-continuous Monitoring of
Intraperitoneal Volume Using Segmental Bioimpedance in Peritoneal
Dialysis Patients. This research explored whether bioimpedance
techniques can be used to monitor the dynamics of intraperitoneal
volume. This oral presentation will be given by Fansan Zhu, PhD on
Thursday, Nov. 2 at 5:54 p.m. in room 290 (TH-OR095).
- Impact of Transition of Care Visits
on Readmission Rates in Dialysis Patients. This study
investigated if introduction of value based transition of care
visits after hospital admissions are associated with improved
readmission rates. This oral presentation will be given by Terry L.
Ketchersid, MD, MBA on Saturday, Nov. 4 at 5:30 p.m. in room 292
(SA-OR036).
- Factors Associated with
Gastrointestinal Bleeding in End Stage Renal Disease Patients.
This research investigated if demographic and clinical
characteristics are predictive of gastrointestinal bleeding. This
poster presentation will be given by Thomas C. Blanchard, PhD on
Thursday, Nov. 2 from 10:00 a.m.-12:00 p.m. (TH-PO777).
- Effects of Predictive Modeling
Assisted Care Interventions on Hospitalization Rates in
Hemodialysis Patients. This research investigated the impacts
of a pilot program that utilizes predictive modeling to assist in
identification of patients at risk for hospitalization thereby
allowing clinicians to intervene in a timely manner. This poster
presentation will be given by David F. Sweet, MSN on Friday, Nov. 3
from 10:00 a.m.-12:00 p.m. (FR-PO897).
In North America alone, Fresenius Medical Care’s research
efforts involve the contributions of more than 1,200 employees, and
the company’s contract clinical research division comprises a
network of over 450 principal investigators at more than 260 sites
representing 160 medical practices. The nature of dialysis care
allows FMCNA to collect substantial amounts of data during routine
treatments, including data on more than 1 million patients, more
than 250 million dialysis treatments and billions of medication
administrations and laboratory results.
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier health care
company focused on providing the highest quality care to people
with renal and other chronic conditions. Through its
industry-leading network of dialysis facilities, outpatient cardiac
and vascular labs, and urgent care centers, as well as the
country’s largest practice of hospitalist and post-acute providers,
Fresenius Medical Care North America provides coordinated health
care services at pivotal care points for hundreds of thousands of
chronically ill customers throughout the continent. As the world’s
largest fully integrated renal company, it offers specialty
pharmacy and laboratory services, and manufactures and distributes
the most comprehensive line of dialysis equipment, disposable
products and renal pharmaceuticals. For more information, visit the
FMCNA website at https://fmcna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171102006457/en/
Fresenius Medical Care North AmericaKate DobbsVice
President of Corporate
Communicationskatherine.dobbs@fmc-na.com(781) 699-9039
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024